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Natural killer cell lymphoma (NKCL) constitutes a rare and
aggressive form of non-Hodgkin lymphoma, and there is little
insight into its pathogenesis. Here we show that PRDM1 is a tumor
suppressor gene in NKCLs that is inactivated by a combination of
monoallelic deletion and promoter CpG island hypermethylation.
We observed monoallelic deletion of PRDM1 loci in 8 of 18 (44%)
NKCL cases. The other allele showed signiﬁcant promoter methyl-
ation in 12 of 17 (71%) cases. In support of its role as a tumor
suppressor gene, the reconstitution of PRDM1 in PRDM1-null NK
cell lines led to G2/M cell cycle arrest, increased apoptosis, and
a strong negative selection pressure with progressive elimination
of PRDM1-expressing cells, which was enhanced when IL-2 concen-
tration is limiting. We observed a progressive increase in PRDM1
expression—in particular, PRDM1α—in normal NK cells in response
to IL-2 and in normal NK cells activated with an engineered NK cell
target, K562-Cl9-mb21, suggesting its role in NK cell homeostasis.
In support of this role, knockdown of PRDM1 by shRNA in normal
NK cells resulted in the positive selection of these cells. We iden-
tiﬁedMYC and 4-1BBL as targets of PRDM1 in NK cells. Disruption
of homeostatic control by PRDM1 may be an important pathoge-
netic mechanism for NKCL.
NK-cell activation and homeostasis | neoplastic transformation | biotage
pyrosequencing | CCNG1 | CCNG2
Natural killer (NK) cell malignancies comprise 1–2% of allnon-Hodgkin lymphomas (NHL) (1) and have been classi-
ﬁed into aggressive NK cell leukemia (ANKCL) and extranodal
NK cell lymphoma of nasal type (ENKCL) by the World Health
Organization classiﬁcation (1). These malignancies are clinically
highly aggressive and associated with poor survival (2). The in-
cidence is higher in East Asia and Central and South America
compared with other parts of the world (3). Especially at late-
stage disease, the malignancies are resistant to chemotherapy,
possibly owing to multidrug resistance associated with the ex-
pression of P-glycoprotein, a product of the MDR1 (ABCB1)
gene (4). Several genome-wide studies identiﬁed 6q21 deletion
as the most frequent aberration in these tumors (5–8). We ob-
served a combination of deletions, mutations generating trun-
cated, nonfunctional proteins, and promoter methylation of
PRDM1 in the majority of the NK cell lines studied, supporting
the role of PRDM1 as a tumor suppressor gene in this commonly
deleted region (9). Interestingly, two recent reports (10, 11)
demonstrated frequent mutations of PRDM1 leading to the
formation of nonfunctional proteins in activated B-cell–like
diffuse large B-cell lymphoma (ABC-DLBCL), thus implicating
PRDM1 as a tumor suppressor in this subtype of DLBCL.
PRDM1 is a transcriptional repressor and a master regulator of
the differentiation of B cells into antibody secreting cells (ASC)
(12). The repression ofMYC (13), SPIB, BCL6, ID3, and PAX5 is
required for this function (14). Recently, PRDM1 expression has
been detected in CD8+ and CD4+ T cells with the effector
phenotype (15, 16), and in CD25+ regulatory T cells (16).
Moreover, PRDM1 has been shown to regulate T-cell homeo-
stasis (15, 16). PRDM1 has two alternative promoters—one
generates PRDM1α, which is the functional form of PRDM1,
and the other generates a functionally impaired form of PRDM1
(PRDM1β) that lacks the 101 aa at the N terminus (17). Here,
we validated the frequent inactivation of PRDM1 in NKCL
patient samples predominantly through promoter methylation
and demonstrated the tumor suppressor activities of PRDM1 in
NK cell lines. Furthermore, we demonstrated that the knock-
down of PRDM1 in normal NK cells promotes their growth.
Results
Evaluation of Copy Number Changes of PRDM1. We used the quan-
titative PCR (qPCR) method on genomic DNA of tumor bi-
opsies to quantify the PRDM1 copy number. The method was
validated by comparing the qPCR results with array CGH
(aCGH) data of 6q21 in NK and γδ T-cell lymphoma cell lines.
We observed a high concordance (11 of 11, 100%) of the two
methodologies (Fig. S1A). Because tumor samples contained a
varying proportion of nontumor cells, we studied the effect of the
stromal content in the tumor biopsies on the qPCR assay by
applying it to genomic DNA containing an admixture of DNA
from NKYS [an NK cell line with del(6)(q21)] and DNA from
human tonsil in predetermined ratios. We found that the qPCR
assay was unable to reliably detect the deletion in the presence
of 30% or more tonsil DNA (Fig. S1B). This level of stromal
contamination may cause practical challenges in detecting de-
letion of PRDM1 using qPCR or aCGH and FISH would be
a useful alternative in this setting if tissues are available. We
performed qPCR on the genomic DNA of 18 NKCL cases and
observed deletion in 44% (eight of 18) of the cases (Fig. 1A),
consistent with a previous report showing a 43% (three of seven)
deletion rate obtained with BAC aCGH using a smaller set of
NKCL cases (9). These results indicate that PRDM1 deletion is
a frequent aberration in primary tumors as well. Our estimate
was a minimum approximation, because the qPCR results of two
NKCL cases were ambiguous (Fig. 1A). The aCGH performed
on these two cases was not able to detect 6q21 deletion
encompassing PRDM1, and therefore the 6q21 status in these
cases was regarded as normal. qPCR did not detect deletion in
two NKCL cases that were determined to have deletion by aCGH.
The aCGH data for NKCL cases was obtained through BAC,
Cartes d’Identité des Tumeurs (CIT), or SNP array platforms, and
there were several discrepancies between qPCR and the BAC or
CIT platforms. In contrast, we observed 100% (six of six) corre-
lation of qPCR and the high-resolution SNP array results.
Promoter Methylation of PRDM1 in NKCL Cases. We found that
PRDM1α promoter methylation was associated with repression
of PRDM1α transcription (9) in malignant NK cell lines. We
performed methylation analysis to cross-validate our previous
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ﬁndings using a different experimental platform, and extended
our analysis to include all available NKCL cases. The region for
analysis was extended to include CpG dinucleotides further up-
stream of the transcription start site (TSS; including 25 CpG
dinucleotides between −786 and +1). Nine NK cell lines and 17
NKCL cases were studied along with highly pure (>95% CD56+
CD3− cells) resting and IL-2–stimulated NK cells as control
samples. The methylation proﬁle was variable, including a few
cell lines and a case that were hypomethylated in regions with
methylation in normal NK cells. However, we observed a fre-
quently hypermethylated region compared with normal NK cells
encompassing −449 and −114 bp relative to the TSS [12 of 17
(71%) tumor samples, 5 of 9 (56%) NK cell lines] (Fig. 1B).
Among the 17 cases with deletion and methylation data, 15 of 17
(88.2%) cases demonstrated deletion and/or methylation (three
with only deletion, eight with only methylation, and four with
both). These results indicate that promoter hypermethylation is
a common event and may cooperate with deletions in NK cell
malignancies. We observed silencing of PRDM1α, as determined
with qRT-PCR, in all malignant NK cell lines with promoter
hypermethylation except for one NK cell line having methylation in
one allele and a deleterious mutation in the other (Fig. S2B,Upper).
Mutation Analysis of PRDM1 in NKCL cases. We tested 18 tumor
cases and another EBV-negative NK cell line, IMC-1, in addition
to the NK cell lines reported previously (9). Unlike NK cell lines,
tumor cases did not show any mutation that would result in a
truncated protein. We identiﬁed two SNPs in three NKCL cases:
a missense SNP (position 843 in exon 4, C to G, Asp to Glu; it
is a known germline variant rs811925) in one case and a silent
SNP (position 2376 G to A, Pro to Pro; it is a germline variant
rs1010273) in two cases (Fig. S3 A and B).
PRDM1 Expression in NK Cell Tumor Biopsies and IL-2–Activated
Primary NK Cells. The copy number and epigenetic status of
NKCL cases correlated well with the PRDM1 mRNA levels in
NKCL cases as determined with qRT-PCR. In general, PRDM1
expression was low in cases with deletion, methylation, or both
(Fig. 1C). We used primers (Fig. S2A) speciﬁc for expression of
PRDM1α (Fig. 1C, Lower) or both isoforms (PRDM1 α + β; Fig.
1C, Upper). In most instances PRDM1α and total PRDM1 tran-
script levels were parallel. We had observed up-regulation of
PRDM1α mRNA in normal NK cells on IL-2 stimulation within
a 24-h period (9); now we found that the progressive increase in
PRDM1 expression in primary human NK cells continued for 6
d (Fig. S2C).When the PRDM1α-speciﬁc primers were used for
qRT-PCR, the induction of PRDM1 appeared to be mainly
contributed by PRDM1α; however, PRDM1α mRNA is much
lower in resting primary NK cells compared with PRDM1 (α +
β), as reported previously (18). We assayed PRDM1 expression in
primary NK cells obtained from coculture with the K562-Cl9-
mb21 cells and observed a robust induction of PRDM1α (70-fold)
compared with resting NK cells (Fig. S2D).
Reconstitution of PRDM1 Leads to Impaired G2/M Cell Cycle Progres-
sion and Increases Apoptosis in PRDM1-Null NK Cell Lines. We used
the retrovirus murine stem cell virus (MSCV)-internal ribosome
entry site (IRES)-GFP (known as pMIG) to reconstitute PRDM1
expression in PRDM1-null NK cell lines (KHYG1, KAI3). We
compared the percentage of apoptotic cells in KHYG1 and KAI3
cells transduced with empty vector or PRDM1 using Annexin V
staining and observed increased apoptosis in PRDM1-transduced
populations of KHYG1 (average = 1.5×) and KAI3 (average =
3.9×) cell lines (Fig. 2 A and B) 2 d after transduction. Using
Hoescht 33342 staining, we observed an increase in the per-
centage of cells in G2/M phase (4.6% in KHYG1, 7.3% in KAI3)
with a concomitant reduction in the percentage of cells in Go/G1
(8.8% in KHYG1, 6.2% in KAI3) and S-phases (2.2% in
KHYG1, 1.4% in KAI3) in PRDM1-transduced KHYG1 and
KAI3 cells on day 3 (Fig. 2 C and D).
Ectopic Expression of PRDM1 Exerts a Negative Selection Pressure on
PRDM1-Null NK Cell Lines in an IL-2 Dose-Dependent Manner. We
asked whether reconstitution of PRDM1 expression in PRDM1-
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Fig. 1. PRDM1 is silenced through a combination of deletion and promoter methylation. (A) NKCL cases with or without deletion is determined by the
PRDM1/RPL13A ratio (three replicates), and cases with <0.75 ratio (dashed horizontal line) to that of human tonsil DNA are deﬁned as deleted. The deletion
status of the NKCL cases by aCGH is indicated by + and −. (B) PRDM1α promoter CpG island is hypermethylated in NK cell lines and NKCL cases. Methylation
percentage (three technical replicates) of CpG dinucleotides upstream of the PRDM1α TSS is indicated as a heat map. Resting and activated NK cells (IL-2 for
7 d) are used as negative control samples. (C) qRT-PCR was performed on seven NKCL cases using primers speciﬁc for PRDM1 (α + β) (Upper) and PRDM1α
(Lower). RPL13A was used for normalization. The deletion or methylation status of PRDM1 for each patient is shown. The expression level is expressed as
a ratio of the level for resting NK cells. Data are mean ±SD. Resting human NK cells and activated NK cells derived from 14 d coculture with K562-Cl9-mb21.
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null NK cell lines will exert a negative selection pressure, as in-
dicated by reduction of the percentage of GFP(+) cells over time
in cells transduced with PRDM1 but not those transduced with
empty vector . We quantiﬁed the percentage of GFP(+) cells in
PRDM1-null NK cell lines at different time points (days 2 and
5 for KHYG1 and NK92; days 3 and 6 for KAI3) after trans-
duction with empty vector or PRDM1 and observed a decrease
in the percentage of GFP(+) cells only in PRDM1-transduced
KHYG1, NK92, and KAI3 cells but not in empty vector-trans-
duced cells (24% in KHYG1, 26% in NK92, and 61% in KAI3;
Fig. S4 A–C). Next, we tested whether the rate of selective
elimination of GFP(+) cells in PRDM1-transduced NK cell
lines was inﬂuenced by the concentration of IL-2 in the culture
medium. In this experiment, the NKYS cell line was used as the
negative control, as this NK cell line expresses endogenous
PRDM1 protein (9). We cultured the PRDM1-null KHYG1
cells with progressively lower concentrations (100, 75, 50, and
25 IU) of IL-2 and compared the percentage of GFP(+) cells in
empty vector- or PRDM1-transduced cells after 2 d and 5
d using FACS (Fig. 3 A and B). After 2 d of culture, we observed
a decrease in the percentage of GFP(+) cells (26.7%, 34.3%,
34.2%, and 39.4% in PRDM1-transduced KHYG1 cells cul-
tured in 100, 75, 50, and 25 IU IL-2, respectively) (Fig. 3C,
Left). After 5 d, we observed a more dramatic decrease in the
percentage of GFP(+) cells that is negatively correlated with
the IL-2 concentration (73.1%, 76%, 79.4%, and 85.3% in 100,
75, 50, and 25 IU IL-2–treated cells, respectively; Fig. 3C,
Middle). Similarly, we observed a decrease in the percentage of
GFP(+) cells (average: 41.2%, 39.9%, 44.5%, and 46.4% for
100,75, 50, and 25 IU IL-2, respectively) in PRDM1-transduced
NK92 cells after 3 d of culture. In contrast, we observed a
much smaller (overall 35%) IL-2–independent reduction in
GFP(+) cells in PRDM1-transduced NKYS cells after 5 d (Fig.
3C, Right).
Rate of Apoptosis in PRDM1-Transduced NK Cells Proportionately
Increases with Progressively Decreasing Doses of IL-2 in the Culture
Medium.Next, we asked whether there is an IL-2 dose-dependent
increase in the rate of apoptosis in PRDM1-transduced NK
cells. PRDM1-transduced NK cells had increased Annexin V
staining for all IL-2 concentrations tested (Fig. 3D). In addition,
we observed a progressive increase in the rate of apoptosis
speciﬁcally in PRDM1-transduced cells with decreasing doses
of IL-2 correlating with the higher rate of negative selection
pressure observed in lower IL-2 concentrations (1.08-, 1.24-,
and 1.46-fold in 75, 50, and 25 IU IL-2 compared with 100 IU
IL-2 treatment, respectively). The inverse correlation between
Annexin V staining and the concentration of IL-2 was speciﬁc
for the GFP(+) population in PRDM1-transduced KHYG1
cells (Fig. 3E, Left) and was not observed in GFP(+) and GFP
(−) populations in vector-only transduced KHYG1 cells or in
the GFP(−) population of PRDM1-transduced KHYG1 cells
(Fig. 3E).
Progressive Elimination of PRDM1-Transduced NK Cells on Long-Term
Culture. The percentages of GFP(+) cells in PRDM1 or control
vector-transduced KHYG1 and NKYS cells grown with standard
(75 IU) IL-2 concentrations were quantiﬁed in a time-course
experiment. We observed a time-dependent progressive de-
pletion of GFP(+) cells in PRDM1-transduced KHYG1 cells
(14.3–0.9%; Fig. S5A) and a decrease (37.4–17.1%; Fig. S5B) in
PRDM1-transduced NKYS cells after 5 wk of culture, but there
was no change in the empty vector-transduced KHYG1 (59.5–
56.47%) or NKYS (55.9–60.7%) cells, suggesting that a negative
selection pressure exerted by the ectopic expression of PRDM1
in NK cells led to the elimination of transduced cells. As an
additional control sample, we did not observe any reduction in
GFP(+) cells in hTERT-transduced KHYG1 cells in 18 d (Fig.
S5C). Ectopic expression of PRDM1 and hTERT was conﬁrmed
by q-RT-PCR (Fig. S6 A–C).
Knockdown of PRDM1 Confers a Growth Advantage to Primary NK
Cells. Next, we wanted to test whether knockdown of PRDM1
provides a growth advantage for primary human NK cells. We
quantiﬁed the percentage of GFP(+) cells at different time
points after transduction of PRDM1-expressing NKYS cells
and human peripheral blood NK cells derived from the periph-
eral blood lymphocytes (PBLs) cocultured with K562-Cl9-mb21
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Fig. 2. Reconstitution of PRDM1
in PRDM1-null NK cell lines indu-
ces apoptosis and cell cycle arrest.
(A) PRDM1 induces apoptosis in
NK cell lines. Transduced, unsorted
NK cells were stained with An-
nexin V-PE and tested with FACS.
The rate of apoptosis was de-
termined by measuring the pro-
portion of Annexin V(+) cells in
the GFP(+) population 2 d post-
transduction. (B) Quantiﬁcation
of the rate of apoptosis in GFP(+)
population of vector- or PRDM1-
transduced cells. (C) Cell cycle
proﬁle of vector- or PRDM1 trans-
duced KHYG1 and KAI3 cells. (D)
The change in each cell cycle phase
is calculated as PRDM1 − PMIG 3 d
posttransduction.
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using empty vector or vector expressing PRDM1 shRNA. We
observed a 65% increase in the percentage of GFP(+) cells after
knockdown of PRDM1 in NKYS cells when cells at 7 d after
transduction were compared with 3 d (Fig. 4B). We observed
a 90% increase in GFP(+) cells in PRDM1 shRNA-transduced
primary NK cells between days 4 and 7 and a 245% increase
between days 7 and 10 (Fig. 4C). The functionality of the
PRDM1 shRNA-mir construct and the knockdown of PRDM1
were shown with the luciferase reporter assay and Western
blotting (Fig. S7 B, D, and E).
Altered PRDM1 Expression Is Associated with Changes in Genes
Involved in Cell Cycle and Activation in NK Cells. Next, we wanted
to test whether ectopic expression of PRDM1 in NK cells alters
expression of genes involved in growth by examining a number of
known PRDM1 targets. Select targets were evaluated at a later
time point in NKYS cells compared with the KHYG1 cells
postinfection due to the practical challenges associated with
obtaining sufﬁcient quantity of RNA from sorted cells. We ob-
served a decrease in the expression of MYC, 4-1BBL (TNFSP9
or CD137L), and TNFα. There was a corresponding increase in
the expression of two negative regulators of the cell cycle,
CCNG1 and CCNG2, in KHYG1 cells transduced with PRDM1
(Fig. 5A). In contrast, we observed increased expression of
TNFα, TNFβ, and MYC in PRDM1 shRNA-transduced NKYS
cells compared with the vector-only transduced cells (Fig. 5B).
We also observed a strong reverse correlation of MYC and
PRDM1 mRNA expression levels in IL-2–activated PB NK cells
(Fig. 5C and Fig. S2C, Lower).
Discussion
Tumor development is a multistep process often involving co-
operation between deregulated expression and/or activation of
oncogenes and inactivation of tumor suppressor genes (TSG).
Monoallelic deletions are commonly observed in many cancer
types, and commonly deleted regions contain potential tumor
suppressor genes that may lose function through promoter
methylation or mutations in the remaining allele. Given the
strong inverse correlation between the PRDM1α promoter
hypermethylation pattern and the expression levels of PRDM1α
observed in PRDM1-null NK cell lines and the increase in
PRDM1α expression after treatment with the DNA demethy-
lating drug 5-aza-2-deoxycytidine (9), promoter methylation may
be one of the pivotal mechanisms contributing to the silencing of
PRDM1 in NK cells. The fact that the majority of NKCL cases
have PRDM1 promoter hypermethylation suggests that PRDM1
may have been silenced by the combination of deletion and
promoter methylation. Deleterious mutations may be infrequent
in NKCL cases so that they were not observed in the cases we
studied. However, it is also conceivable that there were sequence
alterations of PRDM1 in the NKCL cases that were not detected,
as deleterious sequence alterations of PRDM1 due to aberrant
RNA editing were observed in some DLBCL cases (11). Another
possibility is that mutations may have been missed because of the
contamination of neoplastic NK cells with normal stromal cells.
However, this possibility is unlikely, because our gene expression
proﬁling and copy number analysis studies (19, 20) on these cases
indicated that the neoplastic NK cells represent the predominant
population in the tumor. Therefore, abnormal hypermethylation
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seemed to account for the vast majority of cases with low
PRDM1 expression. We observed an increase in apoptosis and
cells in G2/M cell cycle in two PRDM1-null malignant NK cell
lines on reintroduction of PRDM1 into the cells; these results
provide experimental support for PRDM1 as a TSG in NK cells.
The concomitant increase in expression of two negative cell-
cycle regulators and a decrease in MYC expression also support
the hypothesis that PRDM1 is a tumor suppressor in NK cells.
Intriguingly, the MYC signature was up-regulated in NKCLs
(20). Two known targets of PRDM1 with growth regulatory
function in B cells, MYC (21) and 4-1BBL (22), were down-
regulated upon expression of PRDM1, suggesting that certain
functional role of PRDM1 is conserved in different lymphocyte
lineages. Induction of the expression of other direct targets of
PRDM1 in NK cells (e.g., TNFα and TNFβ) (18) may cooperate
with the reconstitution of MYC expression in the neoplastic
transformation of NK cells with silenced PRDM1 expression.
Two negative regulators of G2/M cell cycle, CCNG1 and CCNG2
(23), may be indirect targets of PRDM1. In fact, CCNG2 was
shown to be repressed by MYC (24).
The progressive increase in apoptosis and negative selection
observed when the PRDM1-transduced cells were cultured in
decreasing IL-2 concentrations suggests that the tumor sup-
pressor role of PRDM1 in NK cells may be more pronounced
when growth-promoting factor is present at a limiting concentra-
tion, as is likely to be the case in vivo. PRDM1 may play an
important role in the homeostasis of NK cells by preventing
excessive NK cell activation and proliferation, and this may be
the mechanistic basis for the tumor suppressor action of PRDM1
and the negative selection pressure observed in PRDM1-trans-
duced malignant NK cells. This contention is supported by our
ﬁndings in human primary NK cells, in which PRDM1 is up-
regulated on activation with IL-2 and proliferation is enhanced
upon PRDM1 knockdown. A recent report showed enhanced
proliferation of ex vivo-cultured Rag2−/−/prdm1gfp/gfp mouse NK
cells in limiting IL-15 concentrations, suggesting the involvement
of PRDM1 in the control of homeostasis of mouse NK cells (25)
in agreement with our observations. We have demonstrated up-
regulation of PRDM1α in response to IL-2 in 24 h in normal NK
cells from peripheral blood (Fig. S2C, Upper Left). We have ex-
tended this initial observation and showed that the increase in the
transcriptional level of PRDM1α continues slowly and progressively
in 6 d up to 11-fold, further suggesting that PRDM1 may be part of
a negative autoregulatory loop similar to the one observed in T cells
(26), controlling the activation and/or homeostasis of NK cells.
Recently, two groups have independently shown PRDM1 to
be a tumor suppressor gene in ABC-type DLBCL using in vivo
mouse models (27, 28). In ABC-DLBCL, a block in differenti-
ation at the preplasmablast stage of differentiation is postulated
to be the pathogenetic mechanism. However, the concomitant
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Fig. 5. PRDM1 regulates expression of genes in-
volved in cell cycle and activation in NK cells. (A)
qRT-PCR results of target genes regulated by
PRDM1 in vector- or PRDM1-transduced, GFP-sorted
KHYG1 cells 2 d posttransduction. (B) qRT-PCR
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failure to repress certain target genes such asMYC may also play
a role. NK cells may not have as distinct a differentiation stage
transition as that from B cells to plasma cells, but there is evi-
dence that PRDM1 is more highly expressed in the most mature
population (18). Therefore, our results and published literature
suggest that PRDM1 shares certain functions across lymphocyte
lineages and that loss of function of PRDM1 may contribute to
the neoplastic transformation of activated B and NK cells through
overlapping mechanisms. Intriguingly, we encountered difﬁculty
in reconstituting PRDM1 expression. The challenge of ectopic
expression is a common feature of tumor suppressor genes (29)
and notably has been observed for PRDM1 in many instances,
even with the inducible constructs in GC B-cell–derived cell lines
(22). This phenomenon was more obvious when we compared the
mean ﬂuorescence intensity (MFI) of NK cells transduced with
vector, PRDM1, and hTERT (Fig. S8B). We observed lower MFI
and lower numbers of GFP(+) cells with inducible PRDM1
constructs [i.e., PRDM1-ER and PRDM1a-TREmiR30-PIG
(TMP) even before induction, suggesting leaky transgene ex-
pression and selective disadvantage of PRDM1 expression, even
at low expression levels.
In summary, we performed both functional and correlative
studies on PRDM1 in normal and neoplastic NK cells and pro-
vide strong evidence that PRDM1 is a tumor suppressive gene in
NKCLs. Silencing of PRDM1 in NKCL cases is mainly through
cooperation of 6q21 deletion and promoter CpG island hyper-
methylation. Reintroduction of PRDM1 into NK cell lines
lacking its expression enhanced apoptosis and impaired G2/M
cell cycle progression, and these cells are negatively selected in
cell culture. Conversely, knocking down PRDM1 expression
provides a growth advantage to activated PB NK cells. PRDM1
may share important target genes in B and NK cells, such as
MYC, and identifying the essential targets will lead to further
understanding of its pathogenetic mechanisms.
Materials and Methods
Patient Material and Cell Line. The characteristics of NK cell tumor cases and
NK and γδ T-cell lines included in this study have been reported previously
(19, 20) and are summarized in Tables S1 and S2. Genomic DNA extraction
was performed with the standard phenol/chloroform method (9). The four
cell lines, KHYG1, KAI3, NK92, and NKYS, used for transduction studies were
cultured in RPMI-1640 (Gibco-Invitrogen) supplemented with 10% FCS;
penicillin G (100 units/mL) and streptomycin (100 μg/mL); and 75 IU IL-2 (R&D
Bioscience) at 37 °C in 5% CO2.
Primary NK Cell Isolation and Culture. Normal NK cells from PBLs of healthy
donors were isolated through negative selection using anNK Cell Isolation Kit
(Miltenyi Biotec Inc.). Purity of NK cells was validatedwith CD56-APC (Miltenyi
Biotec Inc.) and CD3-PE (Miltenyi Biotec Inc.) staining using FACSCalibur.
Isolated NK cells were cultured as described previously with 200 IU IL-2
(R&D Bioscience).
Full experimental procedure of PRDM1 copy number variation, mRNA
expression, promoter methylation analysis, exon/exon–intron junction se-
quencing, cell cycle and apoptosis assays, PRDM1 reconstitution experi-
ments, PRDM1 shRNA design and knockdown in NK cells, luciferase assay,
and Western blot are presented in SI Materials and Methods.
Note Added in Proof
While this paper was under review, a paper describing similar ﬁndings on
PRDM1 was published (30).
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